Compare Jabil Inc (JBL) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Jabil Inc vs Summit Therapeutics Inc — how do they compare? Jabil Inc trades at $368.9 (market cap $37.37B), while Summit Therapeutics Inc trades at $15.28 (market cap $12.06B). The key difference: Jabil Inc is far larger — about 3.1× Summit Therapeutics Inc's market cap, and Jabil Inc pays a 0.09% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals.
| JBL | SMMT | |
|---|---|---|
Market Cap | $37.37B | $12.06B |
Sector | Technology | Health |
52-Week High | $385.50 | $26.98 |
52-Week Low | $192.49 | $12.55 |
Enterprise Value | $39.90B | $11.39B |
Dividend Yield | 0.09% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JBL trades at $368.37, up 9.43% with strong bullish momentum driven by AI infrastructure demand and recent earnings beats. The stock shows robust technical strength with moving averages signaling buy and price approaching resistance at $371. Fundamentally, revenue growth accelerated to $33.6B in 2026 with net profit margin improving to 2.56%, though valuation multiples remain elevated with P/E at 44.63.
Outlook remains positive with analyst consensus target of $448.29 (22% upside) and 50% buy ratings. Key opportunities include projected AI revenue growth to $20B+ by 2027, while risks include competitive pressures and the stock's premium valuation. Recent UBS upgrade to Buy highlights multi-year AI growth cycle potential.
Summit Therapeutics (SMMT) trades at $15.23, up 2.42% today, with a bullish technical signal and strong analyst consensus. The stock shows mixed earnings performance but benefits from positive news on ivonescimab's regulatory progress and clinical expansions. Despite negative profitability metrics, investor sentiment is buoyed by a high price target of $38.00 and recent partnership announcements in cancer drug development.
Outlook hinges on FDA approval for ivonescimab by November 2026, offering significant upside if successful. Risks include cash burn, ongoing losses, and fiduciary investigations. The stock presents a high-risk, high-reward opportunity for speculative investors betting on clinical successes.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Jabil Inc
Jabil is a global manufacturing solutions provider for industries including healthcare, automotive, and cloud. It offers comprehensive design, engineering, and supply chain management for complex electronic products.
Read more on JBL →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
